Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series. - 2What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- 3Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- 4Planet-eating stars hint at Earth's ultimate fate
- 5Fundamental Home Exercise center Hardware: Amplify Your Exercises
- Famous Versatile Brands: Your Decision
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- It Shouldn’t Be Here: Rescuers Race to Save Whale Stranded in Rare Spot
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- West Bank man indicted for extortion, impersonation of IAF pilot, Mossad agent, illegal entry
- 'Here we go again': Businesses grapple with fuel costs
